JP2022522819A5 - - Google Patents

Info

Publication number
JP2022522819A5
JP2022522819A5 JP2021551939A JP2021551939A JP2022522819A5 JP 2022522819 A5 JP2022522819 A5 JP 2022522819A5 JP 2021551939 A JP2021551939 A JP 2021551939A JP 2021551939 A JP2021551939 A JP 2021551939A JP 2022522819 A5 JP2022522819 A5 JP 2022522819A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
composition according
leucine
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021551939A
Other languages
English (en)
Japanese (ja)
Other versions
JP7555346B2 (ja
JP2022522819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051767 external-priority patent/WO2020178721A1/en
Publication of JP2022522819A publication Critical patent/JP2022522819A/ja
Publication of JP2022522819A5 publication Critical patent/JP2022522819A5/ja
Priority to JP2024155453A priority Critical patent/JP2024170602A/ja
Application granted granted Critical
Publication of JP7555346B2 publication Critical patent/JP7555346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021551939A 2019-03-02 2020-03-02 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 Active JP7555346B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024155453A JP2024170602A (ja) 2019-03-02 2024-09-10 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US62/812,987 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US62/842,296 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US62/888,894 2019-08-19
US201962895144P 2019-09-03 2019-09-03
US62/895,144 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024155453A Division JP2024170602A (ja) 2019-03-02 2024-09-10 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体

Publications (3)

Publication Number Publication Date
JP2022522819A JP2022522819A (ja) 2022-04-20
JP2022522819A5 true JP2022522819A5 (cg-RX-API-DMAC10.html) 2023-03-13
JP7555346B2 JP7555346B2 (ja) 2024-09-24

Family

ID=69845470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021551939A Active JP7555346B2 (ja) 2019-03-02 2020-03-02 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体
JP2024155453A Pending JP2024170602A (ja) 2019-03-02 2024-09-10 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024155453A Pending JP2024170602A (ja) 2019-03-02 2024-09-10 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体

Country Status (25)

Country Link
US (1) US20220142959A1 (cg-RX-API-DMAC10.html)
EP (2) EP4464378A3 (cg-RX-API-DMAC10.html)
JP (2) JP7555346B2 (cg-RX-API-DMAC10.html)
KR (2) KR102941068B1 (cg-RX-API-DMAC10.html)
CN (2) CN119097618A (cg-RX-API-DMAC10.html)
AU (2) AU2020231189B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021017203A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131948A1 (cg-RX-API-DMAC10.html)
DK (1) DK3934637T3 (cg-RX-API-DMAC10.html)
ES (1) ES2990183T3 (cg-RX-API-DMAC10.html)
FI (1) FI3934637T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241150T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068527T2 (cg-RX-API-DMAC10.html)
IL (2) IL321899A (cg-RX-API-DMAC10.html)
LT (1) LT3934637T (cg-RX-API-DMAC10.html)
MA (1) MA55199B1 (cg-RX-API-DMAC10.html)
MD (1) MD3934637T2 (cg-RX-API-DMAC10.html)
MX (2) MX2021010568A (cg-RX-API-DMAC10.html)
PL (1) PL3934637T3 (cg-RX-API-DMAC10.html)
PT (1) PT3934637T (cg-RX-API-DMAC10.html)
RS (1) RS65849B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109512SA (cg-RX-API-DMAC10.html)
SI (1) SI3934637T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400334T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020178721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022125304A1 (en) * 2020-12-10 2022-06-16 Texas Tech University System Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
US20190046486A1 (en) * 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury

Similar Documents

Publication Publication Date Title
HRP20241150T1 (hr) (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga
JP2013518107A5 (cg-RX-API-DMAC10.html)
JP2018193377A5 (cg-RX-API-DMAC10.html)
JP2014530874A5 (cg-RX-API-DMAC10.html)
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
JP2006505587A5 (cg-RX-API-DMAC10.html)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2020530857A5 (cg-RX-API-DMAC10.html)
JP2014516942A5 (cg-RX-API-DMAC10.html)
JP2015528501A5 (cg-RX-API-DMAC10.html)
JP2021073257A5 (cg-RX-API-DMAC10.html)
JP2015516419A5 (cg-RX-API-DMAC10.html)
JP2016530291A5 (cg-RX-API-DMAC10.html)
JP2022532038A5 (cg-RX-API-DMAC10.html)
JP2021510715A5 (cg-RX-API-DMAC10.html)
JP2008508354A5 (cg-RX-API-DMAC10.html)
JP2019502734A5 (cg-RX-API-DMAC10.html)
JP2017508004A5 (cg-RX-API-DMAC10.html)
JP2023517130A5 (ja) Azd1656又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び/又は心筋炎の治療用組成物
JP2012511571A5 (cg-RX-API-DMAC10.html)
JP2022533011A5 (cg-RX-API-DMAC10.html)
CN107320466A (zh) 厚朴酚在制备ndm‑1酶抑制剂中的医用用途
RU2021128588A (ru) Лейцин, ацетиллейцин и родственные аналоги для лечения заболевания
JPWO2023182342A5 (cg-RX-API-DMAC10.html)
JP2024539623A5 (cg-RX-API-DMAC10.html)